GIP and metabolic dysfunction-associated steatotic liver disease: The latest evidence has shown that treatment with dual GLP-1RA/GIP RAs, GLP-1/GCG RAs, or even triple GLP-1/GIP/GCG RAs may be even more effective in the amelioration of MASLD and MASH.